We Are a Research-Driven Biotechnology Company Focused on Targeted Cancer Therapies

Our Mission Is to Improve Therapeutic Outcomes for Patients Living with Cancer

Our Science Targets Tumor Hypoxia for the Treatment of Cancer

Our People Make the Difference

We Are Passionate About Our Mission and Determined to Achieve Success

We Believe that Better Outcomes are within Reach through Targeting Tumor Hypoxia

The Courage of People Living with Cancer Inspires Us to Work Harder

We Approach Our Work with Integrity, Transparency, Conviction, and Humility


Threshold is a clinical stage biopharmaceutical company focused on the discovery and development of cancer therapeutics based on a novel and powerful approach of targeting tumor hypoxia.

Clinical Trials

TH-302, our investigational hypoxia-targeted drug, is being evaluated in two Phase 3 studies, one for soft tissue sarcoma and the other for pancreatic cancer, as well as several earlier-stage trials in various solid tumors and hematological malignancies. Read more about ongoing clinical trials of TH-302.


February 26, 2014

2014 RBC Capital Markets' Global Healthcare Conference

New York, NY
March 4, 2014

Cowen and Company 34th Annual Health Care Conference

Boston, MA
March 11, 2014

26th Annual ROTH Conference

Laguna Nigel, CA
You are now leaving this website. If you would like to continue, click Continue.